Psychedelic Business Spotlight: November 19
This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.
This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.
“Our goal is to provide insight on key parameters that may impact and explain the mechanisms behind low-dose treatments,” says MindMed Executive President Dr. Miri Halperin Wernli.
Drug Enforcement Agency also hugely boosts MDMA and DMT quotas “in response to the nationwide public interest in hallucinogenic controlled substances research.”
Kate Kincaid, who specializes in psychedelic integration and ketamine-assisted therapy, appears on the premiere of our new series “Spotlight in Focus” to share parallels between labor and tripping on psychedelics.
Meet LSA: LSD’s less intense but introspective cousin found in the seeds of morning glories and other plants. Here’s everything you need to know about the origins, effects, and uses of LSA.
There is currently no known cure for dementia, but Return Health CEO Dr. James Kuo says psychedelics offer “unprecedented” potential.
“HPPD is a discomfort. Some people have it for 10, 15, 20 years and they regret the day they did the drug that caused it,” says the CEO of Ehave.
This isn’t the first time the hit songwriter has turned to psychedelics for therapy, either.
University of Auckland researcher hopes the psychedelic treatment will enhance the effect of psychotherapy, easing end-of-life distress in patients.
Alcohol, methamphetamine and cocaine have been linked to increased aggression in men, but psychedelics appear to have opposite effect.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.